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Elevated Expression of Type VIl Collagen in
the Skin of Patients with Systemic Sclerosis
Regulation by Transforming Growth Factor-/3
Lidia Rudnicka,* John Varga,9 Angela M. Christiano,* Renato V. lozzo,l1 Sergio A. Jimenez," and Jouni Uitto**
Departments of *Dermatology, tBiochemistry and Molecular Biology, OMedicine (Rheumatology), and I"Pathology and Cell Biology,
Jefferson Medical College, and Jefferson Institute ofMolecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Abstract
A hallmark of systemic sclerosis (SSc) is the development of
tissue fibrosis. Excessive production of several connective tissue components normally present in the dermis, including type
I, III, V, and VI collagens as well as fibronectin and proteoglycans, is a consistent finding in the skin of SSc patients. Type
VII collagen is a major constituent of anchoring fibrils, present
in the skin at the dermal-epidermal basement membrane zone.
TGF-ft has been shown to upregulate the expression of the type
VII collagen gene. In this study, we assessed the expression of
type VII collagen and TGF-,6 in the skin of patients with SSc.
Indirect immunofluorescence showed an abundance of type VII
collagen in the patients' skin, including the dermis. Ultrastructural analysis of SSc skin revealed an abundance of fibrillar
material, possibly representing type VII collagen. The increased expression of type VII collagen epitopes was accompanied by the elevated expression of immunodetectable TGF-ftl
and TGF-,82. Dermal fibroblasts cultured from the affected individuals showed a statistically significant (P < 0.02) increase in
the expression of type VII collagen at the mRNA level, as detected by reverse transcription-PCR with a mutated cDNA as
an internal standard, and increased deposition of the protein as
assessed by indirect immunofluorescence. Thus, type VII collagen is abundantly present in SSc patients' dermis, a location not
characteristic of its normal distribution, and its aberrant expression may relate to the presence of TGF-,8 in the same topographic distribution. The presence of type VII collagen in the
dermis may contribute to the tightly bound and indurated appearance of the affected skin in SSc patients. (J. Clin. Invest.
1994. 93:1709-1715.) Key words: systemic sclerosis * anchoring fibrils * type VII collagen * tissue fibrosis * transforming
growth factor-,

Introduction

Systemic sclerosis (SSc)' is a connective tissue disease characterized by fibrosis of the skin, subcutaneous tissue, and various
Address correspondence to Jouni Uitto, M.D., Ph.D., Department of
Dermatology, Jefferson Medical College, 233 South 10th Street, Room
450 BLSB, Philadelphia, PA 19107-5541.
Receivedfor publication 17 May 1993 and in revisedform 10 November 1993.
1. Abbreviations used in this paper: 11F, indirect immunofluorescence;
NC, noncollagenous; RT-PCR, reverse transcription-PCR; SSc, systemic sclerosis.

internal organs (1). The most prominent pathologic manifestation of the disease is an abnormal accumulation ofextracellular
matrix components, predominantly collagen types I and III
(2-4). More recent data have also shown an increased expression of type VI collagen, mainly in a perivascular location (5).
In vitro, fibroblast cultures established from SSc patients' involved skin express increased amounts of collagens type I, III,
and V, fibronectin, and proteoglycans (6-1 1), and contain elevated levels of a 1 (I), a2(I), and a 1 (111) collagen mRNAs (1214). Transient transfection assays have also shown increased
activity of the a2(I) collagen promoter-reporter gene construct
in SSc fibroblasts (15), suggesting enhancement of type I collagen gene expression at the transcriptional level.
TGF-3 consists of a family ofclosely related cytokines. Two
members of the family, TGF-f31 and TGF-f32, have been implicated in the pathogenesis of a variety of fibrotic diseases ( 16,
17), and several lines of evidence suggest that TGF-f3 plays a
critical role in the development of tissue fibrosis in SSc. For
example, TGF-f 1 has been shown to stimulate the synthesis of
various connective tissue components by normal fibroblasts in
vitro ( 1 8, 19), and when injected intradermally TGF-f. causes
tissue fibrosis (20). Furthermore, an abundance of TGF-f in
the skin of SSc patients (21, 22) and the responsiveness of SSc
fibroblasts to stimulation by TGF-3 (23, 24) make this growth
factor a potential candidate molecule in the pathogenesis of SSc.
Type VII collagen consists of three identical a I(VII)
chains, each composed of a long collagenous triple-helix
flanked by globular amino- and carboxy-terminal noncollagenous domains (25-27). Type VII collagen is present in human tissues in a restricted distribution, almost exclusively in
the basement membrane zone below stratifying squamous epithelia of the skin, mucous membranes, and the cornea of the
eye. Type VII collagen is the predominant, if not the exclusive,
component of anchoring fibrils, attachment structures which
ensure the integrity of the cutaneous basement membrane
zone (for reviews see references 27, 28). Under in vitro conditions, type VII collagen is synthesized primarily by epidermal
keratinocytes, but dermal fibroblasts have also been shown to
express the type VII collagen gene at a very low level (29, 30).
The synthesis of type VII collagen can be upregulated by TGF,B1 and TGF-f2 both in keratinocyte and fibroblast cultures
(30, 31).
The aim of the present study was to assess the expression
and distribution of type VII collagen and TGF-f in the skin of
SSc patients and to examine the expression of the type VII
collagen gene in SSc fibroblast cultures.

Methods
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
002 1-9738/94/04/1709/07 $2.00
Volume 93, April 1994, 1709-1715

Patients. This study was performed on skin specimens from seven pa-

tients, six of them having a definitive diagnosis of diffuse SSc and one
being suggestive of SSc (Raynaud's phenomenon and positive test for
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antinuclear antibody). Also, dermal fibroblast cultures were established from eight patients with diffuse SSc of recent onset. In one case,
the skin specimens and cultured fibroblasts were obtained from the
same patient. The diagnosis of SSc was made according to the criteria
of the American College of Rheumatology (formerly American Rheumatism Association) (32), and none ofthe patients had a limited form
of SSc. Clinical features and laboratory findings ofthe 15 patients (S 1S 1 5) are summarized in Table I. Control fibroblast cultures were established from eight age- and sex-matched healthy individuals, and normal skin specimens were obtained from three healthy individuals.
Full thickness excisional skin biopsies were obtained from the leading edge of the fibrotic process on the dorsal forearm of SSc patients
and from site-matched areas from healthy individuals. Each specimen
was cut into two pieces. One part was immediately frozen in liquid
nitrogen, and 5-Mim-thick frozen sections were used for indirect immunofluorescence (IIF). The second piece was used to establish fibroblast
cultures. For IIF, cells were grown on chamber slides (Nunc, Inc., Naperville, IL) to subconfluency. All fibroblast cultures were maintained
in DME supplemented with 10% FCS. In experiments testing the effects of TGF-3, the cells were rinsed with PBS and replaced in DME
containing 1% FCS 3 h before addition of 10 ng/ml TGF-#31 orTGF-,32
(provided by Dr. David R. Olsen, Celtrix Laboratories, Santa Clara, CA).
Reverse transcription-PCR (RT-PCR) amplification of type VII
collagen mRNA transcripts. 1 Mug of total RNA isolated from fibroblast
cultures (passages 4-6), established from the skin of healthy normal
donors or from SSc patients, was used to synthesize the first strand
cDNA with avian myeloblastosis virus reverse transcriptase (Bethesda
Research Laboratories, Gaithersburg, MD) using oligo-dT2-18 primers
(33). The total amount of cDNA synthesized served as a template for
the subsequent PCR amplification, and the reaction was catalyzed by
Taq polymerase (Boehringer Mannheim Corp., Indianapolis, IN) in
the presence of 15 MCi of [ a32P]dCTP and 25 pmol of two primers
defining a 382-bp segment in the 3'-end of type VII collagen mRNA
(34). The primers used were: the upstream primer, 5'-AATGATGGCTCTGCTGGTCC-3'; the downstream primer, 5'-CATGCAGAGGAGGAAGAGGCG-3' (Fig. 1). Amplification was performed for 25 cycles (94°C for 45 s, 61 °C for 45 s, and 72°C for 45 s)
using a thermal cycler (Coy Laboratory Products Inc., Ann Arbor,

MI). Differences in the efficiency of PCR amplification were corrected
for by using a cloned cDNA as internal standard which contained complementary sequences for the same primers and yielded the same size
product but contained a single base substitution in the sequence
GAGAAG instead of GAGATG found in the normal sequence (35).
The mutated PCR product could be cleaved by the endonuclease Earl
into 244- and 138-bp fragments (Fig. 1). This homozygous T-to-A
substitution has been detected in two siblings with recessive dystrophic
epidermolysis bullosa (35). The product of PCR amplification was
subcloned into the PCR 1000 vector (Invitrogen, San Diego, CA),
amplified, and the plasmid construct was linearized with restriction
enzyme digestion using EcoRI (Boehringer Mannheim Corp.). 100 pg
of the cDNA containing the mutated sequence (T-to-A substitution)
was used as an internal standard mixed with the cDNA template generated by RT-PCR from RNA isolated from fibroblast cultures established from SSc patients or from matched control individuals. 200 pg of
cDNA containing the internal standard was used for experiments with
cDNA from TGF-#-stimulated fibroblasts.
Each PCR reaction product was extracted with phenol-chloroform,
digested to completion with the restriction enzyme Earl, and subsequently analyzed by electrophoresis on a 4% polyacrylamide gel (33).
The gel was exposed to x-ray film (X-Omat; Eastman Kodak, Rochester, NY) at -70°C for varying time periods, and the autoradiographic
signals were quantitated by scanning densitometry in the linear range
of the autoradiograms. The intensity of the 382-bp band was normalized by the signal from the 244-bp cleavage product derived from the
internal standard. Control experiments indicated that cleavage of the
PCR product containing the Earl site was complete (35).
IIF. The slides containing either skin sections or cultured cells were
rinsed with PBS and fixed with ice-cold 100% ethanol. For detection of
type VII collagen, after a 30-min incubation with 1% BSA in PBS, the
samples were exposed to an anti-type VII collagen mAb (36) (L3D;
provided by Dr. Robert Briggaman, University of North Carolina,
Chapel Hill, NC) for 45 min at room temperature. Similar procedures
were used for the detection ofTGF-, I or TGF-,#2 epitopes using mAbs
(provided by Dr. David R. Olsen, Celtrix Laboratories, Santa Clara,
CA). The slides were then rinsed with PBS and exposed to a rhodamine-conjugated monoclonal anti-mouse IgG antibody (Cappel Labo-

Table 1. Clinical Characteristics of Patients with Systemic Sclerosis
Systemic involvement

Patient

Serum antibodies

Skin involvement

Raynaud's

Patient
number

Age/sex

36/F
58/M
57/F
45/M
60/F
35/F
56/F
70/F
54/F
31/F
38/F
37/F
26/F
34/M
54/F

SI
S2
S3
S4
S5
S6
S7
S8
S9
S10
511
S12
S13
S14
S15

Duration

Degree*

yr

%

<1

25
14
54
45
>60
26
20
45
25
22
25
15
25
1
0

4
<2
<1
<1
<1
<1
<1
<1
2
2
<1
3
<1
<1

Pulmonary4

Renal

Cardiact

Gastrointestinal

phenomenon

ANAI

Anti-TopoI/ACA"

-

-

+
+
+

+
+
+
+
+

+
+
+

-

-

+
+

+
+

-

+

2560
5120
500
640
640
500
5120
2560
ND
>2560
2560
1280
5120
1280
80

+/ND/ND

ND
ND
-

+
+
+
+
+
ND
ND
-

+

+

ND
+
+

+

-

-

-

+
+

+

+
+
+

+
+

ND/ND/ND

* Values indicate semiquantitative estimate of the percentage of body surface area that is affected clinically. The pulmonary and cardiac involvement was determined as described previously (48). 1 ANA, antinuclear antibodies. 1 ACA, anticentromere antibodies. ' ND, no data available.
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Figure 1. Schematic representation of type VII collagen domain organization, as deduced from cloned cDNAs, and the genomic positions of primer sequences used for RT-PCR amplification of type VII
collagen mRNA transcripts. (A) Type VII collagen consists of a central collagenous region depicting characteristic Gly-X-Y amino acid
sequence (filled boxes). This collagenous domain is flanked by a large
amino-terminal NC domain (NC- l) and a smaller carboxy-terminal
NC domain (NC-2) (hatched boxes). (B) The intron-exon organization of the genomic segment corresponding to the collagenous/NC-2
junction in the mRNA (35), as delineated by a bar in A. The sizes
(basepair) of the introns (horizontal line) and exons either in the collagenous (filled boxes) or NC domain (hatched boxes) are indicated.
(C) The positions and nucleotide sequences of the primers used for
PCR amplification of a 382-bp segment from fibroblast mRNA. (D)
The nucleotide sequence of a 49-bp exon within the NC-2 domain.
The upper line depicts a conserved normal sequence (34) while the
lower line depicts a mutated sequence detected in two siblings with
recessive dystrophic epidermolysis bullosa (35). The mutated sequence was used as a template to develop a cloned cDNA which was
used as an internal standard for RT-PCR. As indicated in the text,
the T-to-A substitution creates a restriction enzyme site for the endonuclease EarI, resulting in the cleavage of the 382-bp PCR amplimer
into 244- and 1 38-bp fragments.

382bp-AA.,,
244bp

ratories, Malvern, PA) for 45 min. Nonadherent secondary antibodies
were then rinsed off with PBS. Nonspecific staining was excluded by
performing staining reactions with the secondary antibody only.
Electron microscopy. For ultrastructural analysis, punch biopsies
from two affected patients were fixed in 2.5% glutaraldehyde, 0.1 M
sodium phosphate, pH 7.2, postfixed in OS04, dehydrated in ethanol,
and embedded in Spurr. 1-Mm-thick sections were stained in toluidine
blue, while thin sections were stained with uranyl acetate and lead
citrate, and the samples were examined in a transmission electron microscope (lOOCX; JEOL U.S.A. Inc., Peabody, MA) operated at 80 kV.

Results
RT-PCR demonstrates elevated expression oftype VII collagen
mRNA transcripts in cultured SScfibroblasts. To determine the
levels of type VII collagen mRNAs in cultured SSc and control
fibroblasts, RT-PCR was performed with total RNA isolated
from cultures established from seven healthy donors and seven
SSc patients. An internal standard consisting of a cDNA template with the identical sequence, with the exception of a single
T-to-A nucleotide substitution which created a new restriction
site for Earl endonuclease (see Fig. 1), was included in each
reaction. Scanning densitometry of the RT-PCR products,
after correction by the value from the internal standard (see

X#Wavei

3.4-fold higher
level of type VII collagen mRNA transcripts in fibroblast cultures from SSc patients, as compared with those from healthy
donors (P < 0.02) (Fig. 2). Incubation with TGF-f 1 and TGF(32 increased the expression of type VII collagen in cultured
fibroblasts established from normal controls (5.3- and 6.7-fold,
respectively) and from SSc patients ( 1.5- and 1.3-fold, respectively) (Fig. 3).
Demonstration of elevated type VII collagen expression at
the protein level by IIF. To evaluate the expression of type VII
collagen at the protein level, IIF with an mAb recognizing an
epitope in the amino-terminal noncollagenous (NC) domain
(NC- 1) (37) was performed on cultured SSc and control cells.
As reported previously (29), unstimulated dermal fibroblasts
from healthy controls display a faint, yet clearly detectable,
staining reaction (+) for type VII collagen epitopes (Fig. 4 A).
Fibroblasts from eight SSc patients were stained in parallel with
the same monoclonal anti-type VII collagen antibody (36). In
five cases, an intense (++) to very intense (+++) staining
reaction, as illustrated in Fig. 4 B, could be observed. In the
remaining three cases, no apparent difference between the control and SSc fibroblasts could be noted (not shown). Exposure
of control fibroblasts to either TGF-O1 or TGF-32 resulted in a
marked increase in the immunofluorescence, in accordance
with previous results (30, 31 ). The relative increase after stimulation with TGF-f seemed somewhat less pronounced in SSc
fibroblasts, probably reflecting the higher baseline staining in
unstimulated control cultures. However, the intensity of the
immunofluorescence appeared to be equally strong in both
control and SSc fibroblasts after stimulation with TGF-#.
IIF of skin sections from healthy controls showed an intense staining (+++ or ++++) for type VII collagen at the
dermal-epidermal junction, and similar staining was observed
at the basement membrane zone of the skin specimens from
SSc patients (Fig. 5). In addition, six out of eight SSc patients

Methods), demonstrated on the average an

,

138bp _,
6
4

2

C'

2

C3

C4

C5

C6

C7

iWO

S1

_

S2

-

S3

0

S4

S5

S6

S

Figure 2. RT-PCR of RNA isolated from fibroblasts of normal
healthy controls (Cl-C7) or from patients with SSc (Sl-S7). (A) Autoradiogram representing the 382-bp bands derived from amplification of control or SSc fibroblast mRNA. The 244- and 138-bp bands
reflect the presence of fragments derived from the mutated internal
standard cDNA after digestion with EarI (see Fig. 1). (B) Ratios of
the 382- and 244-bp bands in each lane, as determined by densitometric scanning. The values represent the mean±SE from four separate determinations of the intensity of the bands at different levels
of exposure to x-ray films. The mean value of SSc fibroblast type VII
collagen transcripts, in comparison with controls, is statistically higher
(P < 0.02) by Student's t test.
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TGFP1
TGFP2

-

+

-

-

+

-

-

-

-

+

-

-

+

-

+
-

-

-

-

+

-

+

+
-

Figure 3. Demonstration that TGF-# I and TGF-f32 increase type VII
collagen gene expression in cultured fibroblasts. Cells from two SSc
patients (SScI = S5 and SScII = S6 in Fig. 2) and matched control
cultures were incubated without (-) or with (+) 1O ng/ml of TGF-,B
for 24 h. Type VII collagen mRNA levels were determined by RTPCR, as described in Methods and in Fig. 2, using an internal cDNA
standard. The 382-bp band represents endogenous mRNA, while the
244- and 1 38-bp bands result from digestion of the internal standard
by Earl. The digestion of the internal standard was complete, as
shown in the negative (NEG) control lane. The upper panel depicts
the autoradiogram of the gel containing 32P-labeled PCR products.
The lower panel indicates the relative ratios of 382- and 244-bp bands,
as determined by scanning densitometry (mean±SD of four separate
determinations on the linear range of exposure ofthe autoradiograms).

showed an intense (++ or +++) staining reaction throughout
the dermis (Fig. 5, B and C, and Table II). In two cases (S4 and
S5), the staining reaction appeared to be more intense in the
reticular dermis, as compared with the papillary dermis (Fig. 5
B). In two patients (S2 and S3), the presence of type VII collagen was also noted within the epidermis (Fig. 5 C), and in one
patient (S3) distinct staining reaction for type VII collagen was
also detected in the subcutaneous tissue (Fig. 6 A). Parallel
staining of control skin specimens revealed essentially negative
staining reaction (- or ±) in the epidermis and dermis (Fig. 5
A) and the subcutaneous adipose tissue (Fig. 6 B).
Detection of TGF-,# epitopes in the affected skin of SSc patients. Since TGF-,3 has previously been shown to upregulate
type VII collagen gene expression both at the protein and
mRNA levels (30, 3 1 ), the presence of TGF-#3l and TGF-f2
epitopes was also evaluated in the skin specimens of the eight
patients with SSc and compared with control skin samples
from three healthy individuals. In healthy individuals, the presence of TGF-#3I and TGF-I2 epitopes could be observed in the
epidermis (±, +, or ++), while the staining reaction in the
dermis was essentially negative (Fig. 7, A and B). In SSc patients, TGF-#3l and TGF-f32 epitopes were clearly detectable in
the epidermis and dermis of all patients studied (Fig. 7, C and
D, and Table II). Staining for TGF-l3I and TGF-ff2 epitopes in
subcutaneous tissue was also performed in one healthy control
and three patients with SSc. In the healthy individual, staining
1712

for both forms of TGF-f3 was entirely negative (Fig. 6 D and
Table II). In contrast, in two out of three patients with SSc,
both TGF-f3I and TGF-,32 epitopes were detected (Fig. 6 Cand
Table II). In general, a correlation could be observed between
the relative staining intensity of TGF-f and type VII collagen
epitopes in the dermis of SSc patients (Table II).
Electron microscopy. Ultrastructural analysis of the skin
from two affected patients revealed a normal appearing epidermis with a continuous basement membrane and anchoring fibrils, and the subepidermal region, as expected, contained an
increased amount of collagen arranged in thick interweaving
bundles (not shown). Of particular interest was the observation that the deeper dermis contained numerous aggregates of
filamentous structures which were interspersed between the
collagen bundles and the elastic fibers. These filaments were
15-20 nm in thickness and up to 200 nm in length. In some
instances, these filaments interacted end-to-end, formed elongated structures, and occasionally showed a curvilinear conformation similar to that observed in the anchoring fibrils associated with the basement membrane at the dermal-epidermal
junction (28). These findings suggest that these filaments may
represent abnormal type VII collagen aggregates, but their exact biochemical composition could not be determined.

Discussion
Type VII collagen is the major, if not the exclusive, constituent
of anchoring fibrils (38). These fibrils play an essential role in

Figure 4. IIF staining with anti-type VII collagen mAb L3D of fibroblast cultures established from a healthy control, C5 (A), and a sexand age-matched SSc patient, S5 (B).
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Figure 6. The presence of type VII collagen and TGF-# I epitopes in
the subcutaneous tissue of a patient, S3 (A and C, respectively), while
the immunostaining of the subcutaneous adipose tissue from a normal control skin with respective antibodies (B and D) is entirely negative.

table forms of dystrophic epidermolysis bullosa (27, 39, 40),
and an acquired autoimmune disease, epidermolysis bullosa
acquisita (41 ). To date, no example of pathologic upregulation
of type VII collagen in an ectopic topographic location has
been described. However, a previous ultrastructural study has
indicated the presence of anchoring fibrils in the lung tissue of
patients with idiopathic pulmonary fibrosis; these fibrils were
not detected in normal lungs (42). Since the anchoring fibrils
observed in the lung tissue resemble those found in normal
skin, it is conceivable that type VII collagen levels may also be
increased in the fibrotic lung tissue in SSc.

Figure 5. IIF staining of type VII collagen epitopes within normal skin
(A) and in two patients with SSc, S4 and S2 (B and C, respectively).
Note the strong linear staining for type VII collagen epitopes in the
cutaneous basement membrane zone in all three specimens, as indicated by an arrow in A. The presence of type VII collagen epitopes is
demonstrated in the reticular dermis in a patient with SSc (B, open
arrow) and also within the epidermis (C, asterisk).

stabilizing the association of the basement membrane to the
underlying dermis and, consequently, provide integrity to the
cutaneous basement membrane zone (28). In normal skin, the
distribution of type VII collagen is essentially restricted to the
dermal-epidermal basement membrane zone, the site of anchoring fibrils. Decreased expression of type VII collagen and/
or impaired assembly of this collagen into anchoring fibrils has
been associated with blistering skin diseases, including the heri-

Figure 7. Immunofluorescence staining of normal human skin (A and
B)

or

skin from

recognizing
Note the

in

the

a patient (S3) with SSc (C and D) with antibodies
or TGF fl2 (B and D).
epitopes for TGF-fll (A and

presence

the epidermis

of a relatively faint, yet clearly detectable staining

of normal skin (A and

B), while the staining is

markedly enhanced in the SSc patient's skin (C and D).
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Table II. Presence of Type VII Collagen,
Healthy Controls*

TGF-#I, and TGF-132 Epitopes in the Skin and Subcutaneous Tissue of SSc Patients and
TGF-B2

TGF-ftl

Type VII collagen

Patient

Epidermis

BMZt

Dermis

Subcutaneous

Epidermis

Dermis

Subcutaneous

Epidermis

Dermis

Subcutaneous

Controls
C
C2
C3
SSc patients

-

++++
++++

-

NS
NS
-

++
++
+

+/-

NS
NS
-

+
+
+1-

+/+1-

NS
NS
-

++
++
-

++++
++++
++++
++++
+++
+++
+++
+++

+1_
NS

++++

++++

+

++
++++
++

+

NS

+++
+
++
++
++
++

+++
+
++
+
+
+
+

+

+/-

S2

S9
S10
511

S12
S13
S14
S15

+/+/-

-

++++

+/+/+++

+/+++
+++
++
++
++

+/-

++

+/+1-

NS
NS
NS

+

+1-

++
++
++

+++
++
++
++
++

+

+

+

NS

+/NS

NS
NS

+

NS
+

NS
+
NS
NS
NS

* The intensity of the staining reaction was semiquantitatively expressed as follows: -, negative; +/-, very faint; +, faint; ++, intense; +++ or
++++, very intense; NS, not studied. * BMZ, basement membrane zone.

The results of our study demonstrate that in SSc skin type
VII collagen is present in high amounts, not only in its expected
location at the basement membrane zone but also in the dermis. Ultrastructural studies showed an abundance of fibrillar
structures, which may represent type VII collagen, in the dermis of SSc patients. The accumulation of type VII collagen in
SSc skin was accompanied by the presence of TGF-f 1 and
TGF-32 epitopes. Further studies performed in vitro on dermal fibroblasts showed increased expression of type VII collagen in SSc cells at the mRNA and protein levels. Also, TGF-flI
and TGF-j32 further upregulated the expression of type VII
collagen both at the mRNA and protein levels. Although upregulation was noted in both normal and SSc fibroblasts, the normal cells appeared to be more responsive to TGF-,B stimulation, probably because of lower baseline level of type VII collagen expression in unstimulated control cultures. The higher
baseline level of expression of type VII collagen in SSc cultures
may result from the exposure of the cells to TGF-,B in vivo, and
the attenuated response of SSc fibroblasts to TGF-, is consistent with earlier data demonstrating unresponsiveness of SSc
cells to growth factors ( 15, 43). Also, there was a general correlation between the relative intensity of staining reaction of
TGF-,B and type VII collagen epitopes within individual skin
specimens. Collectively, these results suggest that the abundance of type VII collagen in SSc dermis may result from increased local expression of TGF-f3.
Clinically, induration and thickening of the skin which is
tightly bound to the underlying tissue are the hallmark of SSc.
The presence of type VII collagen and fibrillar structures in the
dermis may provide an explanation for this appearance of the
affected skin in SSc patients, and this effect could be expected
to be detectable only in the affected area of the skin. The accumulation of type VII collagen in the skin could result from
upregulation of the corresponding gene by TGF-,B. In this context, it is of interest to note that TGF-f31 has been shown to
increase its own expression in an autocrine manner, while
TGF-32 increases the expression of TGF-#31 and TGF-f32 (44).
Consequently, an early increase in the local expression of TGF1714

fi 1 or TGF-,B2 could perpetuate their expression, thus resulting
in continued expression of type VII collagen and other TGF-j3responsive genes in chronic fibrotic conditions. Thus, attempts
to counteract the effects of TGF-3 with other cytokines (45,
46) or to inhibit type VII collagen gene expression by novel
approaches, such as the use of antisense oligomers (47), might
be helpful in preventing the progression or even in reversing
some of the clinical manifestations of SSc.
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